Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation

NCT04905251 is registered in ClinicalTrials.gov with Linepharma International LTD as lead sponsor.

NCT NCT04905251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04905251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation
Lead sponsor
Linepharma International LTD
Phase
Observational
Overall status
Terminated
Start date
February 19, 2022
Completion date
February 20, 2024
Enrollment
129 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

medical abortion